SpikImm was founded in 2021 by Truffle Capital and the Institut Pasteur to develop human monoclonal antibodies (mAbs) to prevent COVID-19 infection. SPK001, SpikImm’s lead candidate, originally developed in the laboratory of Humoral Immunology (Institut Pasteur) headed by Dr Hugo MOUQUET, has demonstrated a potent and broad neutralization activity in vitro against SARS-CoV-2 and all pathogenic variants (including Delta and Omicron), as well as a therapeutic efficacy in vivo in mouse and hamster models. SPK001 is developed as a long-acting antibody with a convenient, intramuscular administration for the prevention of COVID-19 (pre-exposure prophylaxis) in immunocompromised patients unable to mount a protective antibody response after vaccination. SpikImm expects to start clinical trials mid-2022.